High Tide To Become Major Player In German Medical Cannabis Market
High Tide, Inc. is a leading community-grown, retail-forward international cannabis company. Its wholly owned subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. In a major move for the company, High Tide has acquired a majority stake in Germany-based Remexian Pharma GmbH.
Founded in 2018 and headquartered just outside of Berlin, Germany, Remexian is an established medical cannabis pharmaceutical company specializing in the importation and wholesale of medical cannabis. As part of its business model, Remexian has a fully certified EU GDP warehouse.
Remexian is currently licensed to import medical cannabis products into Germany from 19 countries, including Canada, which represents approximately 33% of their total imports into Germany. Given its over $1.9 billion in Canadian cannabis sales since adult-use legalization, High Tide is well-positioned to further increase the Canadian share of medical cannabis imports into Germany.
“Remexian is an ideal match for us—not only in its commitment to discount pricing, but also in its operational approach, which mirrors our lowest price guarantee in Canada. We took our time evaluating potential partners and couldn’t be more excited to join forces with the best-in-class team that built Remexian into a national leader. Together, our complementary strengths and deep procurement expertise will create a stronger foundation for growth and further enhance the fundamentals of this business,” said Raj Grover, Founder and Chief Executive Officer of High Tide.
“With this highly accretive acquisition adding approximately C$100 million in topline revenue and significant EBITDA annually, we will meaningfully strengthen our financials, positioning us well to establish a strong foothold in Germany, which will serve as a springboard into other European markets in due course. Our goal in Germany remains clear: to provide the highest quality medical cannabis at the most affordable prices, led by our Canadian house of brands and supplemented by medical cannabis imports from all across the globe,” added Mr. Grover.
“We are truly energized by the strong synergy we’ve found with High Tide, whose impressive scale amplifies our impact in Germany,” said Markus Wenner, Co-Founder of Remexian. “Both of our companies have taken a deliberate, strategic approach to becoming leaders in our respective markets. By combining one of Germany’s largest cannabis distribution networks with High Tide’s unmatched access to Canadian supply, we are setting the stage for unprecedented growth. We at Remexian are looking forward to building this exciting future together with Raj and the talented High Tide team.”
Germany’s Federal Institute for Drugs and Medical Devices (BfArM) recently published medical cannabis import data for the second quarter of 2025, and once again, Germany’s emerging legal medical cannabis industry set a new record for import totals.
In the second quarter of 2025, Germany imported 43.257 tonnes of medical cannabis products according to BfArM’s data. That is an increase over the previous record set in Q1 2025 of 37.519 tonnes, and a significant increase compared to Q2 2024 when Germany imported 11.634 tonnes of medical cannabis products. Below is a graph of historical import totals from BfArM:
Remexian has an annualized revenue and Adjusted EBITDA of €70 million and €15 million, respectively, for the six months ending March 2025. Remexian is currently one of the largest distributors of medical cannabis flower in Germany in terms of total grams sold, distributing the equivalent of 7 tonnes in Q2 2025, representing 16% of the 43 tonnes imported into Germany during the quarter.
